Does the media prefer PRCT or CLPT?

In the previous week, PROCEPT BioRobotics had 1 more articles in the media than ClearPoint Neuro. MarketBeat recorded 3 mentions for PROCEPT BioRobotics and 2 mentions for ClearPoint Neuro. PROCEPT BioRobotics' average media sentiment score of 0.00 beat ClearPoint Neuro's score of -0.07 indicating that PROCEPT BioRobotics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ClearPoint Neuro 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EYE or CLPT?

In the previous week, National Vision and National Vision both had 2 articles in the media. National Vision's average media sentiment score of 0.95 beat ClearPoint Neuro's score of -0.07 indicating that National Vision is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Vision 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ClearPoint Neuro 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, CLPT or CDRE?

Cadre has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ClearPoint Neuro $36.97M 10.46 -$25.54M -$1.01 N/A Cadre $610.31M 2.10 $44.14M $0.89 33.60

Is CLPT or CDRE more profitable?

Cadre has a net margin of 5.80% compared to ClearPoint Neuro's net margin of -71.57%. Cadre's return on equity of 12.39% beat ClearPoint Neuro's return on equity. Company Net Margins Return on Equity Return on Assets ClearPoint Neuro -71.57% -140.96% -36.98% Cadre 5.80% 12.39% 5.08%

Does the media prefer CLPT or CDRE?

In the previous week, Cadre had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 6 mentions for Cadre and 2 mentions for ClearPoint Neuro. Cadre's average media sentiment score of 0.61 beat ClearPoint Neuro's score of -0.07 indicating that Cadre is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cadre 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ENOV or CLPT more profitable?

Enovis has a net margin of -49.92% compared to ClearPoint Neuro's net margin of -71.57%. Enovis' return on equity of 10.32% beat ClearPoint Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Enovis -49.92% 10.32% 4.57% ClearPoint Neuro -71.57% -140.96% -36.98%

Does the media favor ENOV or CLPT?

In the previous week, Enovis had 6 more articles in the media than ClearPoint Neuro. MarketBeat recorded 8 mentions for Enovis and 2 mentions for ClearPoint Neuro. Enovis' average media sentiment score of 0.40 beat ClearPoint Neuro's score of -0.07 indicating that Enovis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ClearPoint Neuro 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KMTS or CLPT?

In the previous week, ClearPoint Neuro had 1 more articles in the media than Kestra Medical Technologies. MarketBeat recorded 2 mentions for ClearPoint Neuro and 1 mentions for Kestra Medical Technologies. ClearPoint Neuro's average media sentiment score of -0.07 beat Kestra Medical Technologies' score of -0.71 indicating that ClearPoint Neuro is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kestra Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative ClearPoint Neuro 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ClearPoint Neuro (CLPT) Competitors

$12.89 0.00 (0.00%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$12.94 +0.05 (+0.43%)

As of 05:48 AM Eastern

Compare

CLPT vs. PRCT, EYE, CDRE, ENOV, and KMTS

Should you buy ClearPoint Neuro stock or one of its competitors? MarketBeat compares ClearPoint Neuro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ClearPoint Neuro include PROCEPT BioRobotics (PRCT), National Vision (EYE), Cadre (CDRE), Enovis (ENOV), and Kestra Medical Technologies (KMTS). These companies are all part of the "medical equipment" industry.

How does ClearPoint Neuro compare to PROCEPT BioRobotics?

PROCEPT BioRobotics (NASDAQ:PRCT) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

In the previous week, PROCEPT BioRobotics had 1 more articles in the media than ClearPoint Neuro. MarketBeat recorded 3 mentions for PROCEPT BioRobotics and 2 mentions for ClearPoint Neuro. PROCEPT BioRobotics' average media sentiment score of 0.00 beat ClearPoint Neuro's score of -0.07 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

PROCEPT BioRobotics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

ClearPoint Neuro has lower revenue, but higher earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	5.14	-$95.57M	-$1.82	N/A
ClearPoint Neuro	$36.97M	10.46	-$25.54M	-$1.01	N/A

PROCEPT BioRobotics has a net margin of -31.82% compared to ClearPoint Neuro's net margin of -71.57%. PROCEPT BioRobotics' return on equity of -27.70% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

PROCEPT BioRobotics currently has a consensus target price of $41.45, indicating a potential upside of 48.96%. ClearPoint Neuro has a consensus target price of $18.00, indicating a potential upside of 39.64%. Given PROCEPT BioRobotics' stronger consensus rating and higher probable upside, equities analysts clearly believe PROCEPT BioRobotics is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

PROCEPT BioRobotics beats ClearPoint Neuro on 11 of the 16 factors compared between the two stocks.

How does ClearPoint Neuro compare to National Vision?

National Vision (NASDAQ:EYE) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

National Vision has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

30.1% of ClearPoint Neuro shares are owned by institutional investors. 2.4% of National Vision shares are owned by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

National Vision presently has a consensus target price of $30.08, suggesting a potential upside of 94.84%. ClearPoint Neuro has a consensus target price of $18.00, suggesting a potential upside of 39.64%. Given National Vision's stronger consensus rating and higher probable upside, equities research analysts plainly believe National Vision is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

National Vision has a net margin of 2.31% compared to ClearPoint Neuro's net margin of -71.57%. National Vision's return on equity of 6.41% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Vision	2.31%	6.41%	2.81%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

In the previous week, National Vision and National Vision both had 2 articles in the media. National Vision's average media sentiment score of 0.95 beat ClearPoint Neuro's score of -0.07 indicating that National Vision is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
National Vision	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

National Vision has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Vision	$2.02B	0.61	$29.60M	$0.57	27.09
ClearPoint Neuro	$36.97M	10.46	-$25.54M	-$1.01	N/A

Summary

National Vision beats ClearPoint Neuro on 11 of the 15 factors compared between the two stocks.

How does ClearPoint Neuro compare to Cadre?

ClearPoint Neuro (NASDAQ:CLPT) and Cadre (NYSE:CDRE) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

ClearPoint Neuro currently has a consensus target price of $18.00, indicating a potential upside of 39.64%. Cadre has a consensus target price of $39.75, indicating a potential upside of 32.94%. Given ClearPoint Neuro's higher probable upside, equities research analysts plainly believe ClearPoint Neuro is more favorable than Cadre.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cadre	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

In the previous week, Cadre had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 6 mentions for Cadre and 2 mentions for ClearPoint Neuro. Cadre's average media sentiment score of 0.61 beat ClearPoint Neuro's score of -0.07 indicating that Cadre is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cadre	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cadre has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	10.46	-$25.54M	-$1.01	N/A
Cadre	$610.31M	2.10	$44.14M	$0.89	33.60

Cadre has a net margin of 5.80% compared to ClearPoint Neuro's net margin of -71.57%. Cadre's return on equity of 12.39% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
Cadre	5.80%	12.39%	5.08%

ClearPoint Neuro has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Cadre has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 44.0% of Cadre shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 30.1% of Cadre shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Cadre beats ClearPoint Neuro on 15 of the 17 factors compared between the two stocks.

How does ClearPoint Neuro compare to Enovis?

Enovis (NYSE:ENOV) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Enovis has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

In the previous week, Enovis had 6 more articles in the media than ClearPoint Neuro. MarketBeat recorded 8 mentions for Enovis and 2 mentions for ClearPoint Neuro. Enovis' average media sentiment score of 0.40 beat ClearPoint Neuro's score of -0.07 indicating that Enovis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ClearPoint Neuro has lower revenue, but higher earnings than Enovis. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.61	-$1.18B	-$19.88	N/A
ClearPoint Neuro	$36.97M	10.46	-$25.54M	-$1.01	N/A

Enovis presently has a consensus target price of $44.50, indicating a potential upside of 87.38%. ClearPoint Neuro has a consensus target price of $18.00, indicating a potential upside of 39.64%. Given Enovis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Enovis is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Enovis has a net margin of -49.92% compared to ClearPoint Neuro's net margin of -71.57%. Enovis' return on equity of 10.32% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

98.5% of Enovis shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Enovis beats ClearPoint Neuro on 12 of the 16 factors compared between the two stocks.

How does ClearPoint Neuro compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

Kestra Medical Technologies has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

ClearPoint Neuro has lower revenue, but higher earnings than Kestra Medical Technologies. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$59.81M	18.93	-$113.81M	-$3.96	N/A
ClearPoint Neuro	$36.97M	10.46	-$25.54M	-$1.01	N/A

30.1% of ClearPoint Neuro shares are held by institutional investors. 3.6% of Kestra Medical Technologies shares are held by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ClearPoint Neuro has a net margin of -71.57% compared to Kestra Medical Technologies' net margin of -171.87%. Kestra Medical Technologies' return on equity of -65.49% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-171.87%	-65.49%	-46.39%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

Kestra Medical Technologies currently has a consensus target price of $27.40, suggesting a potential upside of 41.24%. ClearPoint Neuro has a consensus target price of $18.00, suggesting a potential upside of 39.64%. Given Kestra Medical Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Kestra Medical Technologies is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, ClearPoint Neuro had 1 more articles in the media than Kestra Medical Technologies. MarketBeat recorded 2 mentions for ClearPoint Neuro and 1 mentions for Kestra Medical Technologies. ClearPoint Neuro's average media sentiment score of -0.07 beat Kestra Medical Technologies' score of -0.71 indicating that ClearPoint Neuro is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kestra Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
ClearPoint Neuro	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ClearPoint Neuro beats Kestra Medical Technologies on 9 of the 16 factors compared between the two stocks.

Get ClearPoint Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLPT vs. The Competition

Export

Metric	ClearPoint Neuro	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$386.57M	$7.11B	$6.46B	$11.98B
Dividend Yield	N/A	1.20%	2.67%	5.55%
P/E Ratio	-12.76	45.87	23.87	23.62
Price / Sales	10.46	44.52	513.32	111.43
Price / Cash	N/A	25.19	26.99	37.25
Price / Book	13.02	6.95	10.38	6.66
Net Income	-$25.54M	$159.22M	$3.57B	$337.72M
7 Day Performance	1.98%	-2.02%	-0.90%	-3.71%
1 Month Performance	0.55%	3.39%	3.56%	0.97%
1 Year Performance	-7.47%	-1.02%	23.81%	25.35%

ClearPoint Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLPT ClearPoint Neuro	2.8803 of 5 stars	$12.89 flat	$18.00 +39.6%	-7.5%	$386.57M	$36.97M	N/A	110	Gap Down
PRCT PROCEPT BioRobotics	2.8206 of 5 stars	$27.86 +5.8%	$41.45 +48.8%	-55.8%	$1.50B	$308.05M	N/A	430	Gap Down
EYE National Vision	4.5401 of 5 stars	$16.08 -4.0%	$30.08 +87.1%	-26.6%	$1.34B	$2.02B	28.21	13,138
CDRE Cadre	4.6353 of 5 stars	$30.68 -1.5%	$39.75 +29.6%	-13.4%	$1.33B	$610.31M	34.47	2,533
ENOV Enovis	4.5011 of 5 stars	$21.73 -4.2%	$44.50 +104.8%	-25.3%	$1.31B	$2.25B	N/A	7,802	Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLPT) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ClearPoint Neuro (CLPT) Competitors

CLPT vs. PRCT, EYE, CDRE, ENOV, and KMTS

How does ClearPoint Neuro compare to PROCEPT BioRobotics?

Summary

How does ClearPoint Neuro compare to National Vision?

Summary

How does ClearPoint Neuro compare to Cadre?

Summary

How does ClearPoint Neuro compare to Enovis?

Summary

How does ClearPoint Neuro compare to Kestra Medical Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ClearPoint Neuro (CLPT) Competitors

CLPT vs. PRCT, EYE, CDRE, ENOV, and KMTS

How does ClearPoint Neuro compare to PROCEPT BioRobotics?

Does the media prefer PRCT or CLPT?

Do institutionals & insiders believe in PRCT or CLPT?

Which has more volatility and risk, PRCT or CLPT?

Which has stronger earnings & valuation, PRCT or CLPT?

Is PRCT or CLPT more profitable?

Do analysts rate PRCT or CLPT?

Summary

How does ClearPoint Neuro compare to National Vision?

Which has more volatility and risk, EYE or CLPT?

Do institutionals and insiders hold more shares of EYE or CLPT?

Do analysts prefer EYE or CLPT?

Is EYE or CLPT more profitable?

Does the media favor EYE or CLPT?

Which has higher earnings and valuation, EYE or CLPT?

Summary

How does ClearPoint Neuro compare to Cadre?

Do analysts rate CLPT or CDRE?

Does the media prefer CLPT or CDRE?

Which has stronger earnings and valuation, CLPT or CDRE?

Is CLPT or CDRE more profitable?

Which has more risk and volatility, CLPT or CDRE?

Do insiders and institutionals have more ownership in CLPT or CDRE?

Summary

How does ClearPoint Neuro compare to Enovis?

Which has more risk and volatility, ENOV or CLPT?

Does the media favor ENOV or CLPT?

Which has preferable earnings and valuation, ENOV or CLPT?

Do analysts recommend ENOV or CLPT?

Is ENOV or CLPT more profitable?

Do institutionals & insiders believe in ENOV or CLPT?

Summary

How does ClearPoint Neuro compare to Kestra Medical Technologies?

Which has more risk and volatility, KMTS or CLPT?

Which has preferable earnings & valuation, KMTS or CLPT?

Do insiders & institutionals have more ownership in KMTS or CLPT?

Is KMTS or CLPT more profitable?

Do analysts prefer KMTS or CLPT?

Does the media refer more to KMTS or CLPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools